Mr. Brown, the makeover show’s mental health expert, skipped planned appearances on “CBS Mornings” and the “Today” show, ...

Serenity Cole enjoyed Christmas last month relaxing with her family near her St. Louis home, making crafts and visiting friends.

Researchers have identified a metabolically sensitive cell subtype in the eye's drainage system which shows early signs of ...

BEIJING -- At 61, a retinitis pigmentosa (RP) patient surnamed Zhao has regained her independence after losing her vision, thanks to a groundbreaking gene therapy injection that, within months, ...

A diagnosis of uveal melanoma marks the beginning of a long-term relationship with your medical team. While the focus starts ...

For decades, a genetic test that turned up a mutation linked to inherited blindness was treated as a verdict, not a risk ...

Ocugen, Inc. gene therapy outlook: key 2026 catalysts, Phase 2/3 eye-disease data, BLA plans to 2028, and risks. Click for ...

The announcement comes on the heels of promising preliminary Phase II data, in which OCU410 reduced lesion growth in patients' eyes.

The company has started enrolling patients into a run-in period for the Phase III study, and plans to begin dosing later this ...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

Among other things, we talked about President Trump’s “most-favored nations” policy on drug pricing and why Regeneron is the ...